Recently, Bristol-Meyers Squibb agreed to pay out a total of $515 million nationally (43 states and the Federal Government) to settle civil litigation over several alleged practices, including its marketing of Abilify to treat children and dementia patients, for whom it was not approved.

The settlement also includes allegations that Bristol-Myers Squibb overpriced various drugs and made illegal payments to doctors to promote the sale of some drugs.

Ultimately, what is needed is a deterrent against improper marketing of drugs.